PDC Biotech (Austria) a preclinical-stage biopharmaceutical company focused upon women’s health preterm labor and primary dysmenorrhea, closed a $5.5M Series A financing. Participants include MIG Verwaltungs and Edmond de Rothschild Investment Partners.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb